SCHEMBL3000979

SCHEMBL3000979

O=S(=O)(c1c(F)c(Br)cc(F)c1Br)N1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PROKR1 Q8TCW9 7/20 0.36
FPR2 P25090 6/20 0.36
GAA P10253 1/20 0.35
POLB P06746 1/20 0.34
AR P10275 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAPK1 P28482 1/20 0.33
GBA1 P04062 1/20 0.33
MAPT P10636 3/20 0.33
USP2 O75604 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018343 0.90 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2L3MBTL1PROKR1FPR2
SCHEMBL3015133 0.88 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2L3MBTL1PROKR1FPR2
SCHEMBL3022372 0.88 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2L3MBTL1GAAMAPK1
SCHEMBL3001149 0.87 EPHX2 (0.36) SMN1; SMN2PROKR1FPR2GAAAR
SCHEMBL3015848 0.87 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2L3MBTL1PROKR1FPR2
SCHEMBL3019065 0.86 PROKR1 (0.38) ALDH1A1SMN1; SMN2L3MBTL1PROKR1FPR2
SCHEMBL3006313 0.86 L3MBTL1 (0.37) ALDH1A1SMN1; SMN2L3MBTL1PROKR1FPR2
SCHEMBL3017973 0.86 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2L3MBTL1PROKR1FPR2
SCHEMBL3023374 0.85 PKM (0.45) ALDH1A1SMN1; SMN2L3MBTL1GAAAR
SCHEMBL3000320 0.85 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.